Brief: Vincerx Pharma Announces FDA Clearance Of Ind For Vip943
22/08/2023 12:32
Aug 22 (Reuters) -
* VINCERX PHARMA ANNOUNCES FDA CLEARANCE OF IND FOR VIP943
* VINCERX PHARMA INC: PHASE 1 TRIAL EXPECTED TO BEGIN IN
EARLY Q4
2023
* VINCERX PHARMA INC - PHASE 1 TRIAL EXPECTED TO BEGIN IN
EARLY Q4
2023
* VINCERX PHARMA INC: ALSO EXPECT TO PROVIDE PRELIMINARY
RESULTS
FOR VIP236 BY LATE 2023 OR EARLY 2024
Source text for Eikon: ID:nGNX4MwnkG
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign